Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) saw strong trading volume on Friday . 96,435 shares changed hands during mid-day trading, an increase of 121% from the previous session's volume of 43,541 shares.The stock last traded at $15.00 and had previously closed at $14.72.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Guggenheim assumed coverage on shares of enGene in a research report on Monday, April 15th. They issued a "buy" rating and a $34.00 price objective for the company. UBS Group assumed coverage on shares of enGene in a report on Thursday, March 28th. They set a "buy" rating and a $37.00 target price for the company. SVB Leerink assumed coverage on shares of enGene in a report on Tuesday, February 20th. They set an "outperform" rating and a $31.00 target price for the company. Leerink Partnrs reaffirmed an "outperform" rating on shares of enGene in a report on Tuesday, February 20th. Finally, Wells Fargo & Company assumed coverage on shares of enGene in a report on Monday. They set an "overweight" rating and a $30.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $34.40.
Read Our Latest Research Report on ENGN
enGene Trading Up 5.3 %
The firm has a fifty day moving average price of $16.20.
Insiders Place Their Bets
In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $15.01, for a total value of $68,670.75. Following the completion of the sale, the insider now owns 3,084,107 shares in the company, valued at approximately $46,292,446.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Institutional Trading of enGene
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Fcpm Iii Services B.V. acquired a new position in shares of enGene in the 4th quarter valued at approximately $80,097,000. Omega Fund Management LLC acquired a new position in shares of enGene in the 4th quarter valued at approximately $10,441,000. BVF Inc. IL acquired a new position in shares of enGene in the 4th quarter valued at approximately $20,777,000. Finally, Vivo Capital LLC acquired a new position in shares of enGene in the 4th quarter valued at approximately $6,264,000. Institutional investors and hedge funds own 64.16% of the company's stock.
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
